A national team of experts will advance an innovative biopolymer particle-based platform technology to develop vaccine candidates to protect against biowarfare threats including Q Fever, tularaemia, and melioidosis.
Emerging Australian biotech company Sementis is engaging with Health Security Systems Australia and Australian universities to enhance the ability of its existing vaccine manufacturing technology to pivot, scale and rapidly deploy in response to emerging health and biosecurity challenges.
The initial 12-month collaboration with Sementis will draw on the company’s long-standing partnership with the University of South Australia as well as expert researchers from the Biomedicine Discovery Institute at Monash University and The Australian National University.
A DMTC-led collaboration has been awarded a High Commendation as part of the prestigious Land Forces 2022 Innovation Awards on the first day of the Exposition in Brisbane.
The award of a high commendation recognises the effort of Health Security Systems Australia (a division of DMTC), in partnership with BioCifer Pty Ltd, CSIRO and academic partners University of the Sunshine Coast and The University of Queensland, to develop a rapid diagnostic platform technology that is accelerating point-of-care detection of bacteria and viruses, and providing a capability advantage for deployed ADF personnel. By focussing on addressing the need to build Australian capability in rapid, accurate and low-resource disease detection, this novel technology aims to detect and diagnose multiple pathogens including COVID-19, Nipah virus, Dengue virus, Hendra virus, and bacteria possessing antimicrobial resistance (AMR), which are of concern to both civilian and ADF personnel who travel or are deployed overseas. (more…)
